Bill Text: IL HB3454 | 2021-2022 | 102nd General Assembly | Introduced

---

Bill Title: Amends the Illinois Controlled Substances Act. Provides that a prescriber shall offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when one or more of the following conditions are present: (1) the prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day; (2) an opioid medication is prescribed concurrently with a prescription for benzodiazepine; (3) the patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant. Provides other requirements and exemptions. Makes other changes. Effective January 1, 2022.

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced - Dead) 2021-03-27 - Rule 19(a) / Re-referred to Rules Committee [HB3454 Detail]

Download: Illinois-2021-HB3454-Introduced.html

---

102ND GENERAL ASSEMBLY State of Illinois 2021 and 2022 HB3454 Introduced , by Rep. Marcus C. Evans, Jr. SYNOPSIS AS INTRODUCED:
720 ILCS 570/315.7 new
Amends the Illinois Controlled Substances Act. Provides that a prescriber shall offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when one or more of the following conditions are present: (1) the prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day; (2) an opioid medication is prescribed concurrently with a prescription for benzodiazepine; (3) the patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant. Provides other requirements and exemptions. Makes other changes. Effective January 1, 2022.
LRB102 14181 KMF 19533 b
A BILL FOR
HB3454 LRB102 14181 KMF 19533 b
AN ACT concerning criminal law.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Controlled Substances Act is
amended by adding Section 315.7 as follows:
(720 ILCS 570/315.7 new)
Sec. 315.7. Prescriber requirements; opioid depression.
(a) Notwithstanding any provision of law to the contrary,
a prescriber shall:
(1) Offer a prescription for naloxone hydrochloride or
another drug approved by the United States Food and Drug
Administration for the complete or partial reversal of
opioid depression to a patient when one or more of the
following conditions are present:
(A) The prescription dosage for the patient is 90
or more morphine milligram equivalents of an opioid
medication per day.
(B) An opioid medication is prescribed
concurrently with a prescription for benzodiazepine.
(C) The patient presents with an increased risk
for overdose, including a patient with a history of
overdose, a patient with a history of substance use
disorder, or a patient at risk for returning to a high

HB3454 - 2 - LRB102 14181 KMF 19533 b
dose of opioid medication to which the patient is no
longer tolerant.
(2) Consistent with the existing standard of care,
provide education to patients receiving a prescription
under paragraph (1) of this subsection (a) on overdose
prevention and the use of naloxone hydrochloride or
another drug approved by the United States Food and Drug
Administration for the complete or partial reversal of
opioid depression.
(3) Consistent with the existing standard of care,
provide education on overdose prevention and the use of
naloxone hydrochloride or another drug approved by the
United States Food and Drug Administration for the
complete or partial reversal of opioid depression to one
or more persons designated by the patient, or, for a
patient who is a minor, to the minor's parent or guardian.
(b) This Section does not apply to a prescriber when
prescribing to an inmate or youth under the jurisdiction of
the Department of Corrections or the Department of Juvenile
Justice.
(c) A prescriber who does not comply with subsection (a)
is subject to administrative sanctions under the appropriate
licensing board. This Section does not create a private right
of action against a prescriber and does not limit a
prescriber's liability for the negligent failure to diagnose
or treat a patient.

HB3454 - 3 - LRB102 14181 KMF 19533 b
Section 99. Effective date. This Act takes effect January
1, 2022.